naion semaglutide Risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed - Novo Nordisk Newest Semaglutide/NAION Study Supports Hypothesis

In May 2026, Phase 3 topline results from the TRIUMPH-1 trial across 2,339 participants showed an average 28.3 percent body weight reduction over 80 weeks at the highest dose, with 45.3 percent of those participants losing at least 30 percent of body weight a threshold previously achievable only through surgery

Advanced Medical Weight Loss Solutions That Deliver Real Results We offer a full range of clinically proven, medical weight loss treatments designed to help you lose weight safely, effectively, and sustainably

The obesity pattern of idiopathic intracranial hypertension in men

Varicose veins that were hidden beneath that fat become much more visible